Pethidine (Dolantin) veterinary grade API is supplied as pethidine hydrochloride, CAS 50-13-5, C₁₅H₂₁NO₂·HCl, relative molecular mass 283.79 g/mol. The product is released under two manufacturing codes: PETH-VET-API-01 for solid oral matrices and PETH-VET-API-02 for parenteral and liquid applications. Both materials are white or almost white crystalline powders intended for further pharmaceutical processing into tablets, capsules, powders, granules, premixes, injectable solutions or oral solutions. PETH-VET-API-01 and PETH-VET-API-02 differ principally in particle-size distribution, bulk density and bacterial endotoxin burden. The substance is listed in national controlled-drug schedules; procurement, storage, processing and destruction require licensed premises, restricted-access storage, usage reconciliation and compliance with veterinary controlled-substance regulations.

The hydrochloride salt is selected because it provides freely water-soluble systems for injection and aqueous liquid manufacture, whereas the free base is lipophilic and unsuitable for direct aqueous formulation. Pethidine is a synthetic phenylpiperidine derivative with µ-opioid receptor agonist activity. Analytical profiles identify the N-demethylated metabolite norpethidine as a pharmacologically active impurity and degradation marker requiring chromatographic control. Bulk material should be stored in airtight, light-resistant containers at controlled room temperature; exposure to strong light and oxidising agents accelerates discolouration and ester hydrolysis.

How are release specifications set for parenteral and oral routes under Ph. Eur. and ICH Q3D?

Release specifications combine compendial monograph limits with route-specific controls. Table 1 summarises the typical certificate-of-analysis parameters for both product codes. The acceptance criteria are manufacturer release profiles based on current European Pharmacopoeia general methods and ICH Q3D elemental impurity management; they do not replace an approved veterinary marketing authorisation specification.

For PETH-VET-API-02, bacterial endotoxin control uses Ph. Eur. 2.6.14, with an acceptance limit of <0.25 EU/mg for parenteral-grade material. This limit is tighter than typical oral-grade APIs because pethidine hydrochloride parentals may be administered as intermittent intravenous or intramuscular injections where endotoxin exposure is unacceptable. Elemental impurities are controlled under ICH Q3D Option 1; the manufacturer’s risk assessment identifies no routine addition of palladium, nickel or chromium from the synthetic route, but batch-to-batch verification is performed for lead, cadmium, arsenic and mercury using ICP-MS. Residual solvents are controlled to Ph. Eur. 5.4; class 3 solvents such as ethanol and ethyl acetate are limited to ≤0.5% each, while class 1 solvents must be not detected. Published data on polymorphic variability of pethidine hydrochloride is limited; therefore release identity relies on infrared concordance and melting range rather than a quantitative XRPD limit.

Transfer to solid-dose manufacturing begins with particle conditioning rather than direct compression because pethidine hydrochloride has moderately high aqueous solubility and a cohesive fines fraction. For tablet and capsule intermediates, PETH-VET-API-01 is specified with a laser-diffraction D₉₀ of ≤150 µm under ISO 13320; material outside this range reduces die-fill consistency on high-speed rotary presses. Batch processing records from tableting campaigns show that pre-blending with microcrystalline cellulose and pregelatinised starch in a 600 L bin blender at 12 rpm for 20 min produces acceptable content uniformity when the drug load is not less than 5.0% w/w. Below that concentration, a geometric pre-blend is required before main blending. Compression is performed with 10.0 mm round biconvex tooling, pre-compression force 8–12 kN and main compression force 18–28 kN; ejection force increases above 30 kN if the granulate moisture exceeds 0.5%. Dissolution release testing uses USP <711> Apparatus 2 at 50 rpm in 900 mL of pH 6.8 phosphate buffer; the acceptance criterion is product-specific and must be established for each veterinary marketing authorisation.

Wet granulation may be required for high-dose tablets because the drug substance has a highly soluble fraction that can cause sticking at main compression forces above 25 kN. In those cases, a binder solution of povidone K30 at 2.0–4.0% w/w is prepared in purified water, and the granulate is dried in a fluid-bed dryer with inlet air temperature 55–65 °C until loss on drying is 0.8–1.5%. Overdrying below 0.5% increases friability and capping; residual moisture above 2.0% shortens the compression window and promotes punch filming. Published pethidine-specific granulation data remains limited; these ranges are transferred from general processing of soluble phenylpiperidine hydrochloride salts and require pilot confirmation.

Premix and powder applications require separate segregation control because pethidine hydrochloride is a high-potency controlled substance and is incorporated at low mass fractions in feed or diluent matrices. A stepwise mixing protocol is used: the API is first blended with lactose monohydrate or maize starch at a 1:10 ratio in a 25 L cube blender; the pre-blend is passed through a 500 µm cone mill; the screened pre-blend is then diluted into the final carrier. Blend uniformity is evaluated according to USP <905>, with an acceptance value ≤ 15.0 for the finished blend. Carry-over is controlled by dedicated contact-part cleaning and analytical verification of pethidine residues below 10 ppm or the limit derived from therapeutic carry-over calculations, whichever is lower. Published data for commercial pethidine premix formulations is limited; the equipment sequence and residue limit are provided as process capability expectations under VICH GL18 risk assessment, not as validated regulatory limits for all jurisdictions. Because pethidine is a controlled substance, destruction of floor sweepings, filter socks and rejected blend must follow national controlled-drug disposal regulations, with witnessed weighing and secondary containment.

When capsules, granules and powders demand low-dose content uniformity under high-shear blending

High-shear mixing is not recommended as the initial blending unit operation for pethidine hydrochloride unless the formulation contains a large proportion of free-flowing direct-compression diluent and the API particle size is controlled. Low-dose capsule fills may exhibit over-lubrication if magnesium stearate is used above 0.75% w/w because the hydrophobic lubricant delays dissolution of the freely soluble hydrochloride. Capsule filling on an automatic dosator machine requires granulate bulk density between 0.55 g/mL and 0.70 g/mL; lower bulk density causes weight variation outside the USP <905> acceptance value, while higher density can overfill and damage the capsule shell. Granules for reconstitution use a sugar-free sorbitol or mannitol matrix to avoid incompatibility between reducing sugars and the tertiary amine structure; aqueous granulation at pH below 4.5 reduces free-base precipitation but increases hydrolytic degradation, so the wet mass is processed quickly and dried to 0.8–1.5% moisture.

For capsules, the content uniformity risk is managed by matching the API D₅₀ to the diluent D₅₀ within ±30 µm; larger mismatches produce segregation during capsule filling hopper vibration. Dissolution testing for capsules uses USP <711> Apparatus 1 at 100 rpm in 900 mL of pH 6.8 phosphate buffer; product-specific acceptance is applied. If a granule or powder for oral solution is prepared, a preservative-free single-dose sachet configuration is preferred because pethidine hydrochloride in aqueous solution at neutral pH is subject to oxidative discolouration, and multi-dose containers require preservative efficacy testing under Ph. Eur. 5.1.3.

Pethidine occupies a narrow kinetic niche between morphine and fentanyl in companion-animal protocols.

Compared with morphine sulfate, pethidine hydrochloride shows a faster onset after intramuscular injection because its phenylpiperidine structure confers greater lipid solubility at physiological pH. Published veterinary pharmacokinetic studies in dogs and horses describe a short duration of analgesia, consistent with rapid redistribution and N-demethylation to norpethidine. The practical consequence is that pethidine is generally reserved for short painful procedures or transient perioperative pain, while morphine is preferred for longer postoperative analgesia in canine and feline patients because its duration of action is longer. Pethidine is not a direct substitute for methadone or fentanyl; it shares µ-opioid receptor agonism but differs in potency, active metabolite profile and species-specific adverse-effect burden. In renally compromised animals, repeated pethidine dosing can lead to norpethidine accumulation and neuroexcitation, including tremor and convulsions. This metabolic liability is less prominent with morphine, which is metabolised primarily by glucuronidation, and with fentanyl, which has no active norpethidine analogue in the same pathway. Published direct clinical comparisons in veterinary species are limited; species-specific pharmacovigilance reports should be reviewed before use.

In equine practice, pethidine has been used for colic analgesia, but the potential for central nervous system excitation and the short duration relative to detomidine or butorphanol restrict its use to specific clinician-supervised protocols. The API itself is not formulated with species-specific flavour or stabiliser; each finished product must establish its own stability and residue withdrawal periods under the relevant veterinary medicines regulation.

Injectable solution stabilisation, terminal sterilisation and ampoule compatibility

Parenteral manufacturing with PETH-VET-API-02 requires low-particulate and low-endotoxin material. The API is dissolved in Water for Injections at a typical concentration of 50 mg/mL expressed as pethidine hydrochloride; the solution pH is adjusted to 4.0–5.5 with dilute hydrochloric acid or sodium hydroxide. Above pH 6.0, the free base can precipitate, and hydrolytic degradation of the ethyl ester accelerates; below pH 3.5, the tertiary amine is fully protonated but ampoule glass attack may increase over long-term storage. Nitrogen sparging to dissolved oxygen below 2 ppm and amber glass ampoules are used to limit oxidative discolouration. Terminal steam sterilisation at 121 °C for 15 min corresponds to an F₀ of not less than 15 min; however, feasibility must be confirmed by formulation-specific stability studies because published pethidine-specific degradation data in low-oxygen parenteral formats is limited. Aseptic filtration through 0.22 µm sterilising-grade membranes followed by terminal autoclaving should be supported by full-container stability data. The use of antioxidants such as sodium metabisulfite at 0.1% w/v is product-specific and may require compatibility testing in elastomeric closures. Silicone gaskets and type I borosilicate glass vials are preferred; polyvinyl chloride infusion bags should be avoided unless compatibility data confirm no adsorption or plasticiser leaching.

Bulk powder is hygroscopic only to a limited extent, but moisture access at relative humidity above 60% produces surface dissolution and caking. Containers are double polyethylene bags inside a fibre drum with desiccant. Photostability follows ICH Q1B Option 2; exposed powder shows discolouration at 1.2 million lux·h visible light and 200 W·h/m² UV, so amber packaging and low-UV lighting in dispensing suites are required. Oxidative degradation markers include pethidine N-oxide and meperidinic acid; HPLC methods using Ph. Eur. 2.2.29 are capable of separating these from the main peak when the column temperature is maintained at 40 °C. If the primary container is breached under humid conditions, loss-on-drying and appearance testing should be performed before further processing. The retest period is assigned on the basis of annual stability data; no claim beyond the approved retest date is made.